Date: 2014-10-23
Type of information: IPO
Company: DBV Technologies (France)
Investors:
Amount: € 90 million
Funding type: IPO
Planned used:
Others: * On October 23, 2014, DBV Technologies, a clinical-stage specialty biopharmaceutical company, announced that the underwriters in its recently announced global offering have exercised in full their options to purchase an additional 401,045 ordinary shares in the global offering, of which 320,836 ordinary shares in the form of 641,672 American Depositary Shares, or ADSs, are to be purchased in the underwritten public offering in the United States, Canada and countries outside of France and 80,209 ordinary shares are to be purchased in the concurrent registered private placement through international underwriters in France and countries outside of the United States and Canada. The settlement of the new shares is expected to occur on October 24, 2014. * On October 22, 2014, DBV Technologies announced the pricing of its global offering of 2,673,641 ordinary shares, of which 2,138,913 ordinary shares in the form of 4,277,826 American Depositary Shares, or ADSs, at a price to the public of $21.64 per ADS, before underwriting discounts in an underwritten public offering in the United States, Canada and countries outside of France and 534,728 ordinary shares at a price of €34.00 per share, before underwriting discounts in a concurrent registered private placement through international underwriters in France and countries outside of the United States and Canada. The price per ADS in the U.S. offering represents an offering price of €34.00 per ordinary share at an assumed exchange rate of $1.2727 per Euro. All of the ordinary shares and ADSs are being offered by DBV. In addition, DBV has granted the U.S. underwriters a 30-day option to purchase up to an additional 320,836 ordinary shares in the form of 641,672 ADSs in connection with the U.S. offering and the international underwriters a 30-day option to purchase up to an additional 80,209 ordinary shares in connection with the international registered private placement. The closing of the U.S. offering and the international registered private placement will be conditioned on each other and is expected to occur on October 24, 2014, subject to customary closing conditions. * On October 10, 2014, DBV Technologies announced that it intends to offer and sell, subject to market and other conditions, up to 2,673,641 of its ordinary shares in a global offering, which is comprised of an offer of ordinary shares in the form of American Depositary Shares, or ADSs, in the United States, Canada and countries outside of France in an underwritten public offering through U.S. underwriters and an offer of ordinary shares in France and countries outside of the United States and Canada in a concurrent registered private placement through international underwriters. DBV intends to grant the U.S. underwriters a 30-day option to purchase additional ordinary shares in the form of ADSs in connection with the U.S. offering and the international underwriters a 30-day option to purchase up to additional ordinary shares in connection with the international registered private placement, up to a maximum of 3,074,686 ordinary shares to be sold in the global offering. The closing of the U.S. offering and the international registered private placement will be conditioned on each other. Each of the ADSs offered in the U.S. offering represents the right to receive one-half of one ordinary share. Application has been made for listing of the ADSs on the Nasdaq Global Select Market under the symbol “DBVT.” Citigroup Global Markets Inc., Leerink Partners LLC and Bryan, Garnier & Co. are acting as joint global coordinators and joint book-running managers of the global offering. Citigroup Global Markets Inc. and Leerink Partners LLC are acting as representatives of the U.S. underwriters. Citigroup Global Markets Limited is acting as representative of the international underwriters. The U.S. underwriters are Citigroup Global Markets Inc, Leerink Partners LLC, Bryan, Garnier & Co and Trout Capital LLC. The international underwriters are Citigroup Global Markets Limited and Bryan, Garnier & Co.
Therapeutic area: Allergic diseases - Immunological diseases
